Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with <sup>177</sup>Lutetium.
Yael Kusne(WinnMed), Mrinal M. Patnaik(Mayo Clinic), Daniel S. Childs(Mayo Clinic in Arizona), Stephanie Pritzl(Mayo Clinic in Arizona), Jason S. Starr(Jacksonville College), Mohamad Bassam Sonbol(WinnMed), Oliver Sartor(Mayo Clinic), Tanios Bekaii‐Saab(WinnMed), Osama Mosalem(Mayo Clinic in Florida), Christy M. Finke(Mayo Clinic), Timothy J. Hobday(Mayo Clinic), Jacob J. Orme(Mayo Clinic), Þorvarður R. Hálfdánarson(Mayo Clinic), Terra L. Lasho(Mayo Clinic)
Cited by 2
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k